PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12
The license agreement covers exclusivity in North America and co-exclusivity in Europe, Central and South America. Kits will be developed for the complete portfolio of PerkinElmer platforms, including AutoDELFIA, DELFIA Xpress and manual DELFIA platforms.
A team consisting of Dr. Ulla Wewer at the University of Copenhagen, Dr. Michael Christiansen from Statens Serum Institut (SSI) and Dr. Kevin Spencer at the Harold Wood Hospital in England have done all of the groundwork and tested ADAM12 in several thousand samples from pregnant women to investigate its importance for prediction of chromosomal disorders.
ADAM12 also shows potential to provide an early indicator of IUGR and pre-eclampsia, for which there are no current screening mechanisms. Early studies at the University of Copenhagen, SSI and Harold Wood have shown that ADAM12 levels were reduced at 10-14 weeks in pregnancies that developed pre-eclampsia and were greatly reduced in those exhibiting both pre-eclampsia and low birth weight.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.